ICH Q11 Development and manufacture of drug substances (chemical ...
...This document describes approaches to developing and understanding the manufacturing process of the drug substance. It also provides guidance on what information should be provided in sections 3.2.S.2.2 ? 3.2.S.2.6 (ICH M4Q)....
https://www.ema.europa.eu/en/scientific-guidelines/ich-q11-development-manufacture-drug-substances-chemical-entities-biotechnological-biological-entities
ICHQ11 v1
...This guideline describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) Sections 3.2.S.2.2 ? 3.2.S.2.6 (ICH M4Q)....
https://database.ich.org/sites/default/files/Q11_Guideline.pdf
ICH HARMONISED TRIPARTITE GUIDELINE
...GICAL ENTITIES) Q11 1. Introduction This guideline describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) Section....
https://database.ich.org/sites/default/files/Q11%20Guideline.pdf
ICH guideline Q11 on development and manufacture of drug substances ...
...This guideline describes approaches to developing process and drug substance understanding and also provides guidance on what information should be provided in CTD sections 3.2.S.2.2 - 3.2.S.2.6....
https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnological-biological-entities_en.pdf
Q11 Development and Manufacture of Drug Substances | FDA
...This guidance describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module......
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q11-development-and-manufacture-drug-substances
ICH HARMONISED TRIPARTITE GUIDELINE - PMDA
...GICAL ENTITIES) Q11 1. Introduction This guideline describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) Section....
https://www.pmda.go.jp/files/000156285.pdf
Q11 Development and Manufacture of Drug Substances
...It is particularly relevant to the preparation and organization of the contents of sections 3.2.S.2.2 - 3.2.S.2.6 of Module 3 of the Common Technical Document (ICH M4Q)....
https://www.fda.gov/media/80909/download
ICH Official web site : ICH
...This new guidance describes approaches to developing process and drug substance understanding and also provides guidance on what information should be provided in CTD sections 3.2.S.2.2 ? 3.2.S.2.6....
https://ich.org/news/ich-q11-reaches-step-4-ich-process
Eudralex Volume 3 ICH Guideline Q11 on Development and Manufacture of ...
...This guideline describes approaches to developing process and drug substance understanding and also provides guidance on what information should be provided in CTD sections 3.2.S.2.2 - 3.2.S.2.6....
https://www.gmp-compliance.org/guidelines/gmp-guideline/eudralex-volume-3-ich-guideline-q11-on-development-and-manufacture-of-drug-substances-chemical-entities-and-biotechnological-bio
Q11 Step 5 Development and manufacture of drug substances
...This guideline describes approaches to developing and understanding the manufacturing process of the drug substance, and also provides guidance on what information should be provided in Module 3 of the Common Technical Document (CTD) sections 3.2.S.2.2 ? 3.2.S.2.6 (ICH M4Q)....
https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q11-development-and-manufacture-drug-substances-chemical-entities-and-biotechnologicalbiological-entities_en.pdf